@ARTICLE\{IMM2007-04475,
    author       = "S. Haugb{\o}l and L. H. Pinborg and L. Regeur and E. S. Hansen and T. G. Bolwig and F. {\AA}. Nielsen and C. Svarer and L. T. Skovgaard and G. M. Knudsen",
    title        = "Cerebral {5-}HT2A receptor binding is increased in patients with Tourette's syndrome",
    year         = "2007",
    month        = "apr",
    keywords     = "Positron emission tomography, human, brain, serotonin",
    pages        = "245-252",
    journal      = "The International Journal of Neuropsychopharmacology",
    volume       = "10",
    editor       = "",
    number       = "2",
    publisher    = "Cambridge University Press",
    url          = "http://dx.doi.org/10.1017/S1461145706006559",
    abstract     = "Experimental and clinical data have suggested that abnormalities in the serotonergic neurotransmissions in frontal-subcortical circuits are involved in Tourette's syndrome. To test the hypothesis that the brain's {5-}HT2A receptor binding is increased in patients with Tourette's syndrome, {PET} imaging was performed. Twenty adults with Tourette's syndrome and 20 healthy control subjects were investigated with {PET}-[18F]altanserin using a bolus-infusion protocol. Regions of interest were delineated automatically on co-registered {MRI} images, and partial volume-corrected binding parameters were extracted from the {PET} images. Comparison between control subjects and Tourette's syndrome patients showed increased specific [18F]altanserin binding, not only in the a-priori selected brain regions hypothesized to be involved in Tourette's syndrome, but also post-hoc analysis showed a global up-regulation when testing for a overall difference with a randomization test (p<0.03). Increased {5-}HT2A receptor binding was found not only in regions closely related to subcortical regions in patients with Tourette's syndrome, but also in most other brain regions. Our data suggest that the serotonergic transmitter system is pathophysiologically involved in Tourette's syndrome and that a clinical trial with {5-}HT2A receptor antagonists may be justified."
}